Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L7SY
|
||||
| Former ID |
DIB000905
|
||||
| Drug Name |
Delequamine hydrochloride
|
||||
| Synonyms |
Delquamine; RS-15385-197; RS-15385-FP; RS-15385-FPh
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Male sexual disorders [ICD10:F52] | Discontinued in Phase 3 | [1] | ||
| Company |
Roche Bioscience
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H27ClN2O3S
|
||||
| Canonical SMILES |
S(=O)(=O)(N1[C@H]2C[C@@H]3N(C[C@H]2CCC1)CCc1c3ccc(c1)OC<br />)C.Cl
|
||||
| CAS Number |
CAS 119942-75-5
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008832) | ||||
| REF 2 | Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol. 1996 May;118(1):63-72. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.